Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 1999

View Archived Issues

Preclinical study of TRAIL points to promise as antitumor agent

Rigel and Pfizer to collaborate in identifying drug targets in allergy and asthma

Cell Genesys reports preclinical results for Parkinson's disease gene therapy

EMEA marketing approval for Triacelluvax

Cortecs signs distribution agreement with Merck KGaA for Macritonin in Spain

Neurogen updates partnered drug development programs

N- and L-type calcium channel inhibitors developed by Ajinomoto

Production and use of KSHVIL-6/vMIP-1alpha II peptides, antibodies and antisense oligonucleotides

New GABA-A receptor ligands for anxiety, convulsions

Roche patents novel compounds interacting with group II mGluR

1,6-Naphthyridine anticonvulsants in research at SmithKline Beecham

Preparation and use of nAChR modulators disclosed by NeuroSearch

Promising early clinical results presented this week for ABT-378 in combination with ritonavir

ImmunoGen and SB enter agreement for colorectal cancer treatment

Matrix Pharmaceutical: Q4 and FY 1998 highlights

Grant to be used to study effect of P-113 in chronic lung infections

Agouron's new anti-HIV compounds profiled at AIDS conference

NIH-sponsored human clinical trials to begin with Novavax spermicide

Schering-Plough seeks approval for pediatric use of Nasonex nasal spray

First phase I clinical trials commence with NX-211

Single-dose phase I/II trial results in HIV+ adults given PRO-542 presented

Progenics identifies novel anti-HIV product

Orthovisc introduced in Israel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
New assay for drug discovery against chemo-induced peripheral neuropathy
BioWorld Science
A group led by researchers at Boston Children’s Hospital established a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity...